Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. (Nasdaq: ALT) is a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapeutics and vaccines addressing critical public health and biodefense needs. Leveraging the unique properties of its proprietary platform technologies, Altimmune is adept at swiftly designing product candidates targeting a range of diseases, including respiratory conditions, chronic infections, and cancer.
Altimmune's advanced Densigen™ T-cell platform technology is specifically designed to guide the immune system's response against complex disease targets by focusing on multiple antigens simultaneously. Another key platform, RespirVec™, uses needle-free intranasal delivery for faster and broader immunity against pathogens compared to traditional vaccines.
The company is also heavily involved in addressing obesity and liver diseases through its innovative peptide therapeutics. The lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist under development for obesity and non-alcoholic steatohepatitis (NASH). Pemvidutide has shown promising results in clinical trials, achieving significant weight loss and liver fat reduction. It has received Fast Track designation from the U.S. FDA for treating NASH, highlighting its potential to meet significant unmet medical needs.
Altimmune's pipeline also includes HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. However, the company has recently decided to cease further development on HepTcell based on Phase 2 trial findings.
Financially, Altimmune maintains a robust cash position, enabling it to advance its clinical programs. Recent financial results indicate a focused investment in research and development, ensuring continued progress in its pipeline.
Significant recent achievements include:
- Positive top-line results from the 48-week MOMENTUM Phase 2 obesity trial of pemvidutide.
- Ongoing Phase 2b IMPACT trial of pemvidutide in MASH with top-line results expected in Q1 2025.
- Strong financial position with substantial cash reserves to support ongoing and future research activities.
Altimmune is poised at the forefront of developing transformative therapies for serious health conditions, potentially delivering significant advancements in patient care.
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat content (LFC)
- Up to 55.6% of subjects achieved LFC normalization
- Significant improvements in body weight and liver inflammation markers
- 94.4% of subjects achieved ≥30% relative reduction in LFC
- Well-tolerated with 2.9% adverse event discontinuations
Pemvidutide is currently in a Phase 2b IMPACT trial for metabolic dysfunction-associated steatohepatitis (MASH), with results expected in Q1 2025.
Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, announced its participation in the Leerink Partners Therapeutics Forum on July 9 and 10, 2024, in Boston, MA. The company's management team will engage in one-on-one meetings with institutional investors. This forum will include panel discussions with leading physicians focusing on autoimmune and metabolic diseases. Altimmune aims to leverage these interactions to advance its strategic objectives and investor relations.
Altimmune (Nasdaq: ALT) announced the unexpected passing of their Chief Financial Officer, Richard Eisenstadt, on June 24, 2024. President and CEO Vipin K. Garg expressed deep sorrow on behalf of the company, highlighting Eisenstadt's leadership and personal qualities. While the search for his replacement is underway, the finance and accounting team will manage his responsibilities.
Altimmune presented data from its 48-week Phase 2 MOMENTUM trial of pemvidutide at the ADA’s 84th Scientific Sessions. The trial focused on pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity treatment. Key findings show that 78.1% of weight loss was due to fat reduction, with only 21.9% from lean mass. The trial involved 391 subjects, achieving mean weight losses of 10.3%, 11.2%, 15.6%, and 2.2% for the 1.2 mg, 1.8 mg, 2.4 mg doses, and placebo, respectively. Additionally, pemvidutide improved serum lipids and blood pressure without notable cardiac events. These findings suggest that pemvidutide may offer a promising, long-term treatment for obesity.
Altimmune, a clinical-stage biopharmaceutical company, presented data on its GLP-1/glucagon dual receptor agonist candidate, pemvidutide, at the American Diabetes Association’s 84th Annual Scientific Sessions. Pemvidutide showed significant reductions in pro-inflammatory serum lipids, including total cholesterol, LDL-C, and triglycerides, by 28%, 26%, and 38% respectively. These lipid reductions were not linked to weight loss, implying a direct impact on lipid metabolism. The Phase 1 study involved 34 subjects receiving varying doses of pemvidutide or placebo for 12 weeks. Additionally, reductions in GlycA and GlycB, markers of systemic inflammation, and decreases in systolic and diastolic blood pressure were noted, suggesting a potential lowered cardiovascular disease risk.
Altimmune, a clinical-stage biopharmaceutical company listed on Nasdaq under the symbol ALT, will participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day on June 26, 2024. Company leaders, including CEO Vipin Garg, Ph.D., and Chief Scientific Officer Scott Roberts, Ph.D., will discuss insights from the American Diabetes Association's Scientific Sessions during a fireside chat at 9:30 a.m. EDT. The session will be webcast and accessible via the Events section of the Altimmune website.
Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, will present data on their investigational drug, pemvidutide, at the American Diabetes Association’s (ADA) 84th Scientific Sessions from June 21-24, 2024, in Orlando, FL.
Pemvidutide, a GLP-1/glucagon dual receptor agonist, is being developed for obesity and NASH treatment. Two key presentations include:
- Dr. John J. Suschak discussing the effects of pemvidutide on cardioinflammatory lipids on June 22 at 4:45 PM EDT.
- Dr. Louis Aronne presenting 48-week Phase 2 trial data on June 23 at 1:45 PM EDT, also featured in ADA's Press Program.
Details will be available on Altimmune's website.
Altimmune presented new data at the EASL International Liver Congress 2024 highlighting the potential of pemvidutide in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH). The data from Phase 1 trials indicate significant improvements in non-invasive tests, suggesting potential histologic benefits by Q1 2025. The trials show that pemvidutide's dual GLP-1/glucagon agonism could outperform GLP-1 alone in resolving MASH and reducing fibrosis. Additionally, lipidomic profiling supports its potential in addressing MASH-related co-morbidities like cardiovascular disease. Pemvidutide is currently being evaluated in a Phase 2b trial.
On May 29, 2024, Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor conferences. The company management will attend the Jefferies Global Healthcare Conference in New York on June 5, 2024, with a fireside chat at 2:00 p.m. ET. They will also attend the Goldman Sachs Global Healthcare Conference in Miami Beach on June 12, 2024, with a fireside chat at 9:20 a.m. ET. Both sessions will be webcast and accessible via the Events section of Altimmune's website.
Altimmune, a clinical-stage biopharmaceutical company, announced new data on pemvidutide, a novel peptide-based GLP-1/glucagon dual receptor agonist, at the EASL International Liver Congress™ 2024 in Milan. Pemvidutide is under development for treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). The data highlights its anti-inflammatory and anti-fibrotic properties in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD). Presentations include:
- Dr. Sarah Browne on metabolic dysfunction-associated steatohepatitis activity and fibrosis.
- Dr. Scot Roberts on plasma lipidomic profiling in subjects with obesity.
- Dr. Shaheen Tomah on noninvasive tests indicating histologic response in MASLD subjects.
These presentations will occur on June 5, 2024, at 8:30 am CEST, with posters displayed throughout the congress.
FAQ
What does Altimmune, Inc. specialize in?
What are the main products in Altimmune's pipeline?
What is pemvidutide?
Has pemvidutide received any regulatory designations?
What is Densigen™ platform technology?
How does the RespirVec™ platform work?
What recent financial results has Altimmune reported?
What are the current clinical trials for pemvidutide?
What is the status of HepTcell™ development?
Where can I find more information about Altimmune?
